130 results
Page 3 of 7
8-K
EX-99.1
kz396g3bje erw
4 Nov 21
Adaptimmune Reports Third Quarter Financial Results and Business Update
7:40am
8-K
EX-99.1
qos3os2 esolu728ig
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
x6pk1zsogsvz
7 Sep 21
Adaptimmune Enters into a Strategic Collaboration with Genentech to Research, Develop, and Commercialize Cancer-targeted Allogeneic T-cell Therapies
7:08am
8-K
EX-99.1
uxhi d3fjfm
6 May 21
Adaptimmune Reports First Quarter Financial Results and Business Update
7:38am
8-K
EX-99.1
zisgqgn c2t
25 Feb 21
Adaptimmune Reports Fourth Quarter / Full Year 2020 Financial Results and Business Update
7:37am
8-K
EX-99.1
ukyhjt5j
20 Nov 20
Regulation FD Disclosure
7:36am
S-3ASR
wxzty09
10 Aug 20
Automatic shelf registration
5:01pm
424B5
omlwtx99
2 Jun 20
Prospectus supplement for primary offering
5:05pm
424B5
xvvip67np wcb2lrpa2
1 Jun 20
Prospectus supplement for primary offering
6:06am
8-K
EX-99.1
i4ds wrb8c8mp
14 May 20
Adaptimmune Reports Q1 Financial Results
7:37am
8-K
EX-99.1
1jwjk
12 May 20
SPEAR T-cells Derived from Stem-Cells Kill Cancer Targets - Adaptimmune Presents Advances from its Allogeneic Platform at ASGCT Annual Meeting
10:54am